Sule Mene, as the Owner of MENE Research, has been instrumental in shaping the organization into a leading Clinical Research Organization (CRO) since its establishment in 2003. Located in the innovative GOSB Technopark in Kocaeli, Turkey, MENE Research leverages its strategic position within one of...
Sule Mene, as the Owner of MENE Research, has been instrumental in shaping the organization into a leading Clinical Research Organization (CRO) since its establishment in 2003. Located in the innovative GOSB Technopark in Kocaeli, Turkey, MENE Research leverages its strategic position within one of the country’s most advanced industrial zones to provide high-quality services to the pharmaceutical industry. Sule's extensive expertise spans various therapeutic areas, including oncology, dermatology, cardiology, and psychiatry, allowing MENE Research to offer specialized clinical trial management services tailored to the unique needs of each client.
Under Sule's leadership, MENE Research has successfully executed numerous key projects, focusing on enhancing the efficiency and effectiveness of clinical trials. The organization utilizes cutting-edge technologies, such as Clinical Trial Management Systems (CTMS) and Electronic Data Capture (EDC), to streamline operations and ensure compliance with regulatory standards. Sule’s commitment to excellence is reflected in her ability to lead cross-functional teams, fostering collaboration and innovation to drive project success.
MENE Research is not only recognized for its reliable and high-quality services but also for its dedication to advancing clinical research practices in Turkey and beyond. Sule Mene’s vision for the company emphasizes the importance of building strong partnerships within the pharmaceutical industry, enhancing the overall landscape of clinical research. Her strategic insights and deep understanding of the industry position MENE Research as a trusted partner for pharmaceutical companies seeking to navigate the complexities of clinical trials and bring new therapies to market efficiently.
